Medical Cannabis in Germany: From the BtMG to the Cannabis Act?

Recommendation
12/13 November 2025
How to implement EU-GMP Chapter 8
According to a draft version for the German Cannabis Law (Cannabisgesetz, CannG), cannabis for medical purposes will no longer fall within the scope of the Narcotics Law (Betäubungsmittelgesetz, BtMG). The working draft provides a separate chapter for this special cannabis. However, this is still under discussion.
What may change
It concerns medicinal cannabis, which is of plant origin, as well as synthetically produced cannabinoids, which correspond to the natural group of active ingredients, the cannabinoids found in the plant (e.g. Dronabinol). With the new law, it is expected that also Dronabinol is to be removed from the scope of the BtMG and then regulated in the CannG. Accordingly, the production of dronabinol (and of preparations / dosage forms containing dronabinol) will no longer be subject to BtMG authorization (a manufacturing authorization according to EU GMP is, of course, still required, e.g. for the manufacture of Dronabinol Capsules).
In addition, the chapter contains regulations around prescription, import and export permission, cultivation and its supervision. However, the cultivation of cannabis for medical purposes in Germany is still expected to take place exclusively under the responsibility of the German Cannabis Agency.
Within terms of operation of a public pharmacy or a hospital pharmacy, cannabis from a state-controlled cultivation for medical purposes may also be imported and exported without a (BtMG) permit.
For more information please see the article (in German) Apotheken dürfen Genusscannabis weder anbauen noch abgeben published by DAZ (Deutsche Apotheker Zeitung) online.
Related GMP News
02.04.2025BfArM Guideline for the Application for a Licence to Cultivate Cannabis
27.03.2025Can RWD support Medical Cannabis Evalution?
27.03.2025Omission of the German Cannabis Monograph
04.03.2025FDA requests Information on the Use of Cannabis Products in Animals
04.03.2025How to Classify Borderline Products?
30.01.2025FDA seeks Feedback on Opiate Alkaloid Content of Poppy Seeds